Molecular pathogenesis of pituitary disorders

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 1, 2002, Pages 61-78

  Prezant, Toni R ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; DOPAMINE 2 RECEPTOR; ESTROGEN; GONADORELIN; GONADORELIN RECEPTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; PROTEIN P16; PROTEIN P27; PROTIRELIN; PROTIRELIN RECEPTOR; RETINOBLASTOMA PROTEIN; SOMATOSTATIN RECEPTOR; THYROTROPIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ACROMEGALY; ADENOHYPOPHYSIS; ALBRIGHT SYNDROME; ANIMAL MODEL; CARCINOGENESIS; CARNEY COMPLEX; CHROMOSOME SEGREGATION; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; HORMONAL REGULATION; HORMONE DEFICIENCY; HORMONE RELEASE; HYPERPLASIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOPHYSIS TUMOR; MOUSE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE; ONCOGENE C FOS; ONCOGENE C MYB; ONCOGENE C MYC; ONCOGENE RAS; PATHOGENESIS; PITUITARY TUMOR TRANSFORMING GENE; PROLACTINOMA; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036308028     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200202000-00009     Document Type: Review

References (174)

1. Molecular basis of pituitary dysfunction in mouse and human
2. Signaling mechanisms in pituitary morphogenesis and cell fate determination
3. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse
4. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency
5. Syndromic short stature in patients with a germline mutation in the lim homeobox Ihx4
6. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome
7. Dosage requirement of Pitx2 for development of multiple organs
8. Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg->Cys at codon 120 (R120C)
9. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit1 gene
10. PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency
11. "Hot spot" in the PROP1 gene responsible for combined pituitary hormone deficiency
12. A mutation in the POU-homeodomain of Pit1 responsible for combined pituitary hormone deficiency
13. Mutation of the POU-specific domain of Pit1 and hypopituitarism without pituitary hypoplasia
14. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans
15. Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NRSA1/SF-1) and adrenocortical insufficiency
16. DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita
17. Inherited disorders of the gonadotropin hormones
18. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins
19. Tbx19, a tissue-selective regulator of POMC gene expression
20. Pituitary lineage determination by the Prophet of Pit1 homeodomain factor defective in Ames dwarfism
21. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1
22. Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary tumor susceptibility
23. Multistep control of pituitary organogenesis
24. SOD-A multigenic disorder?
25. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia
26. Pit1 gene expression in the human pituitary and pituitary adenomas
27. Prop-1 gene expression in human pituitary tumors
28. How a tadpole becomes a frog
29. Molecular basis of the little mouse phenotype and implications for cell type-specific growth
30. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse
31. The Dwarfs of Sindh: Severe growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene
32. Familial dwarfism due to a novel mutation of the growth hormone-releasing hormone receptor gene
33. Extensive phenotypic analysis of a family with growth hormone (GH) deficiency caused by a mutation in the GH-releasing hormone receptor gene
34. Pituitary-adrenal axis regulation in CRH-deficient mice
35. Leukemia inhibitory factor mediates the hypothalamic pituitary adrenal axis response to inflammation
36. Linkage of congenital isolated adrenocorticotropic hormone deficiency to the corticotropin releasing hormone locus using simple sequence repeat polymorphisms
37. Pituitary adenomas in mice transgenic for growth hormone-releasing hormone
38. Ectopic secretion of corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and biochemical study
39. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice
40. The immuno-neuroendocrine interface
41. Pituitary-directed leukemia inhibitory factor transgene forms Rathke's cleft cysts and impairs adult pituitary function. A model for human pituitary Rathke's cysts
42. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice
43. Growth hormone-releasing hormone-producing tumors: Clinical, biochemical, and morphological manifestations
44. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene
45. Genetic basis of endocrine disease. 6. Molecular basis of familial human growth hormone deficiency
46. Heterozygous gsp mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone
47. Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors
48. A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans
49. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: Analysis of gene sequence and mRNA expression
50. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors
51. Structure of the thyrotrophin-releasing hormone receptor in human pituitary adenomas
52. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumor
53. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor
54. Delayed puberty and hypogonadism caused by mutations in the follicle-stimulating hormone beta-subunit gene
55. Mutations in gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism
56. Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas
57. The pituitary "incidentaloma"
58. Acromegaly
59. Genetics of Prolactinomas
60. Cushing's disease
61. Gonadotroph adenomas
62. Thyrotropin-secreting pituitary tumors
63. Clonal origin of pituitary adenomas
64. Clinically nonfunctioning pituitary tumors are monoclonal in origin
65. Molecular genetic studies of sporadic pituitary tumors
66. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker
67. Molecular screening of pituitary adenomas for gene mutations and rearrangements
68. A genetic model for colorectal tumorigenesis
69. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins
70. Pathogenesis of Pituitary Tumors
71. Somatotrophinomas in multiple endocrine neoplasia type 1: A review of clinical phenotype and insulin-like growth factor-1 levels in a large multiple endocrine neoplasia type 1 kindred
72. Genetic testing in presymptomatic diagnosis of multiple endocrine neoplasia
73. Mutation and cancer: Statistical study of retinoblastoma
74. Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors
75. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma
76. Positional cloning of the gene for multiple endocrine neoplasia-type 1
77. Menin, the product of the MEN1 gene, is a nuclear protein
78. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
79. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors
80. Molecular tools for presymptomatic testing in multiple endocrine neoplasia type 1
81. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: Clinical features and inheritance pattern
82. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma
83. Chromosome 5 allele loss in human colorectal carcinomas
84. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene
85. Somatic mutation of the MEN1 gene in parathyroid tumours
86. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas
87. Mutations of the MEN1 tumor suppressor gene in pituitary tumors
88. Molecular characterization of the men1 tumor suppressor gene in sporadic pituitary tumors
89. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours
90. The MEN-1 gene is rarely down-regulated in pituitary adenomas
91. The McCune-Albright syndrome: A lethal gene surviving by mosaicism
92. Activating mutations of the stimulatory G protein in the McCune- Albright syndrome
93. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas
94. Analysis of the Gs alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues
95. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas
96. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant
97. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas
98. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas
99. Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes
100. Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex)
101. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex
102. Mutations in the protein kinase A R1 alpha regulatory subunit cause familial cardiac myxomas and Carney complex
103. Familial prolactinoma
104. Mutation analysis of the MEN1 gene in Israeli patients with MEN1 and familial isolated hyperprolactinemia
105. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1
106. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese
107. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene
108. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13
109. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism
110. Isolated familial somatotropinomas: Establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12
111. Inhibitors of mammalian G1 cyclin-dependent kinases
112. The hallmarks of cancer
113. Effects of an Rb mutation in the mouse
114. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB
115. Loss of heterozygosity at the retinoblastoma locus in human pituitary tumors
116. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus
117. Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary tumors
118. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island
119. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice
120. Reduced expression levels of the cell-cycle inhibitor p27Kip1 in human pituitary adenomas
121. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors
122. Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation and proteolytic processing
123. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis
124. Frequent loss of the P1 61NK4a gene product in human pituitary tumors
125. Frequent inactivation of the pl 6 gene in human pituitary tumors by gene methylation
126. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line
127. p53 gene mutations in pituitary adenomas: Rare events
128. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions
129. Purine-binding factor (nm23) gene expression in pituitary tumors: Marker of adenoma invasiveness
130. Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis
131. Pituitary tumors in mice exposed prenatally to diethyl-stilbestrol
132. Selective expression of estrogen receptor alpha and beta isoforms in human pituitary tumors
133. Differential expression of estrogen receptor-beta (ER beta) in human pituitary tumors: Functional interactions with ER alpha and a tumor-specific splice variant
134. Increased basic fibroblast growth factor in plasma from multiple endocrine neoplasia type 1: Relation to pituitary tumor
135. The endogenous fibroblast growth factor-2 antisense gene product regulates pituitary cell growth and hormone production
136. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas
137. Pituitary hyperplasia induced by ectopic expression of nerve growth factor
138. Dopamine agonists and pituitary tumor shrinkage
139. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas
140. Molecular pharmacology of somatostatin receptor subtypes
141. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
142. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas
143. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment
144. Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas
145. Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells
146. Mutations of the G protein-coupled receptors of the hypothalamo-pituitary-gonadal axis. Where do we stand?
147. H-ras mutations in human pituitary carcinoma metastases
148. ras mutations in human prolactinomas and pituitary carcinomas
149. c-myc, c-fos, and c-myb gene expression in human pituitary adenomas
150. Transforming DNA sequences present in human prolactin-secreting pituitary tumors
151. Heparin-binding secretory transforming gene (hst) facilitates rat lactotrope cell tumorigenesis and induces prolactin gene transcription
152. Prolactinomas express human heparin-binding secretory transforming gene (hst) protein product: Marker of tumour invasiveness
153. Isolation and characterization of a pituitary tumor-transforming gene (PTTG)
154. Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)
155. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
156. hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG
157. Expression of pituitary-tumour transforming gene in colorectal tumours
158. Human pituitary tumor-transforming gene induces angiogenesis
159. A novel binding factor facilitates nuclear translocation and transcriptional activation function of the pituitary tumor-transforming gene product
160. Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: Evidence from live cell imaging
161. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity
162. Activation of mitogen-activated protein kinase cascade regulates pituitary tumor-transforming gene transactivation function
163. Identification of c-myc as a down-stream target for pituitary tumor-transforming gene
164. Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product
165. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase
166. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis
167. Oncogene activation in pituitary tumors
168. Securin degradation is mediated by fzy and fzr, and is required for complete chromatid separation but not for cytokinesis
169. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division
170. Strain difference in regulation of pituitary tumor transforming gene (pttg) in estrogen-induced pituitary tumorigenesis in rats
171. An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: Evidence for hPTTG family
172. New pituitary oncogenes